Stay updated on Pembrolizumab in Refractory Meningioma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Refractory Meningioma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page. Its footer revision changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-20T13:41:35.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-13T14:15:20.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page previously contained a 403 Forbidden message and a navigation link; these deletions indicate the error state content is removed and normal page content is expected to be shown.
    Difference
    0.5%
    Check dated 2026-09-29T16:53:10.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed when loading the study record, replacing the study details with a standard error screen. The navigation to Home remains visible, but substantive content is blocked by the error.
    Difference
    18%
    Check dated 2026-09-22T22:14:22.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.7.0 appears in the page footer, replacing v3.6.6. This reflects a platform update and does not modify the study details or user interactions.
    Difference
    0.1%
    Check dated 2026-09-15T21:59:01.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The page shows a new site revision number (v3.6.6) following an update. This reflects a software/interface update and does not change trial content or data.
    Difference
    0.1%
    Check dated 2026-09-01T18:56:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Refractory Meningioma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Refractory Meningioma Clinical Trial page.